LIGAND OF PERIPHERAL IMIDAZOLINE RECEPTORS BASED ON AMIDES OF HETEROCYCLIC ACIDS C7070: EFFECT ON ISHEMIZED TISSUES
Introduction: In this regard, the study of pleiotropic hepatoprotective properties of the agonist of peripheral imidazoline receptors C7070 seems interesting from an applied point of view.
Materials and Methods: Models of a skin flap on a feeding leg, ischemia-reperfusion of the liver and rat heart isolated from Langendorff (ischemia-reperfusion and doxorubicin cardiomyopathy) were used.
Results and Discussion: The I2 agonist C7070 at a dose of 10 mg/kg 4.5-fold prevents the increase in ALT and AST (332.56 ± 22.05/825.49 ± 22.46 ALT/AST 526.90 ± 17.97/1045.16 ± 80.02 units/l in control) and 2.5 times reduces the areas of ischmeic damage and necrosis (0.058 ± 0.029/0.046 ± 0.013 mm2) in the modeling of 15-minute ischemia liver. Moxonidine and metformin had a hepatoprotective effect: 44.99 and 36.88 for moxonidine (ALT and AST) and 34.20 / 21.02 for metformin (ALT / AST). The coefficients of histological hepatoprotective activity: 72.33 and 38.96 (moxonidine and metformin).
C7070 (10.0 mg/kg) has a pronounced dermatoprotective activity and prevents the formation of necrosis on days 3 and 7 of the pathology by 40%. The dermatoprotective activity of metformin (50 mg/kg) from 3 to 10 days decreases from 81% to 92%. The dermatoprotective activity of moxonidine (1 μg/kg) was maximal on the 7th day and was 76%.
In the isolated rat heart, the C7070 showed a protective effect in ischemia-reperfusion and on the model of doxorubicin cardiomyopathy. The STTi index: 8.3, 1.5; 7.9 and 7.8 U. in control, C7070, moxonidine and metformin.